Beverly A. (Hrsg.) Teicher
Anticancer Drug Development Guide
Preclinical Screening, Clinical Trials, and Approval
Ebook (PDF Format)
This unique volume traces the critically important pathway by which a molecule becomes an anticancer agent. The recognition following World War I that the administration of toxic chemicals such as nitrogen mustards in a controlled manner could shrink malignant tumor masses for relatively substantial periods of time gave great impetus to the search for molecules that would be lethal to specific cancer cells. Weare still actively engaged in that search today. The question is how to discover these anticancer molecules. Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval, Second Edition describes the evolution…
Mehr
Beschreibung
This unique volume traces the critically important pathway by which a molecule becomes an anticancer agent. The recognition following World War I that the administration of toxic chemicals such as nitrogen mustards in a controlled manner could shrink malignant tumor masses for relatively substantial periods of time gave great impetus to the search for molecules that would be lethal to specific cancer cells. Weare still actively engaged in that search today. The question is how to discover these anticancer molecules. Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval, Second Edition describes the evolution to the present of preclinical screening methods. The National Cancer Institute's high-throughput, in vitro disease-specific screen with 60 or more human tumor cell lines is used to search for molecules with novel mechanisms of action or activity against specific phenotypes. The Human Tumor Colony-Forming Assay (HTCA) uses fresh tumor biopsies as sources of cells that more nearly resemble the human disease. There is no doubt that the greatest successes of traditional chemotherapy have been in the leukemias and lymphomas. Since the earliest widely used in vivo drug screening models were the murine L 1210 and P388 leukemias, the community came to assume that these murine tumor models were appropriate to the discovery of antileukemia agents, but that other tumor models would be needed to discover drugs active against solid tumors.
CHF 212.50
Preise inkl. MwSt. und Versandkosten (Portofrei ab CHF 40.00)
Versandkostenfrei
Produktdetails
Weitere Autoren: Andrews, Paul A. (Hrsg.)
- ISBN: 978-1-59259-739-0
- EAN: 9781592597390
- Produktnummer: 37298025
- Verlag: Humana Press
- Sprache: Englisch
- Erscheinungsjahr: 2004
- Seitenangabe: 451 S.
- Plattform: PDF
- Auflage: 2004
20 weitere Werke von Beverly A. (Hrsg.) Teicher:
Preclinical Screening, Clinical Trials, and Approval
Ebook (PDF Format)
CHF 259.50
Preclinical Screening, Clinical Trials, and Approval
Ebook (PDF Format)
CHF 220.50
Preclinical Screening, Clinical Trials, and Approval
Ebook (PDF Format)
CHF 106.50
Preclinical Screening, Clinical Trials, and Approval
Ebook (PDF Format)
CHF 141.50
Preclinical Screening, Clinical Trials, and Approval
Ebook (PDF Format)
CHF 275.50
Preclinical Screening, Clinical Trials, and Approval
Ebook (PDF Format)
CHF 259.50
Preclinical Screening, Clinical Trials, and Approval
Ebook (PDF Format)
CHF 106.50
Bewertungen
0 von 0 Bewertungen
Anmelden
Keine Bewertungen gefunden. Seien Sie der Erste und teilen Sie Ihre Erkenntnisse mit anderen.